Dihydroartemisinin-piperaquine versus chloroquine in the treatment of Plasmodium vivax malaria in Thailand: a randomized controlled trial.

Journal article

BACKGROUND: Chloroquine (CQ) remains the treatment of choice for Plasmodium vivax malaria. Initially confined to parts of Indonesia and Papua, resistance of P. vivax to CQ seems to be spreading, and alternative treatments are required. METHODS: We conducted a randomized controlled study to compare the efficacy and the tolerability of CQ and dihydroartemisinin-piperaquine (DP) in 500 adults and children with acute vivax malaria on the Northwestern border of Thailand. RESULTS: Both drugs were w...

Expand abstract

Authors: Phyo, A; Lwin, K; Price, R; Ashley, E; Russell, B

• Publication status: Published
• Journal: Clinical infectious diseases : an official publication of the Infectious Diseases Society of America
• Volume: 53
• Issue: 10
• Pages: 977-984
• Publication date: 2011-11-01
• DOI: 10.1093/cid/cir631
• EISSN: 1537-6591
• ISSN: 1058-4838
• Language: English
• Keywords: Risk Factors; Plasmodium vivax; Quinolines; Female; Adult; Middle Aged; Male; Antimalarials; Child, Preschool; Child; Infant; Young Adult; Chloroquine; Humans; Adolescent; Malaria, Vivax; Artemisinins; Parasitic Sensitivity Tests; Treatment Outcome; Recurrence